Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 3/2007

01-03-2007 | Article

Adiponectin complexes in human cerebrospinal fluid: distinct complex distribution from serum

Authors: C. M. Kusminski, P. G. McTernan, T. Schraw, K. Kos, J. P. O’Hare, R. Ahima, S. Kumar, P. E. Scherer

Published in: Diabetologia | Issue 3/2007

Login to get access

Abstract

Aims/hypothesis

Adiponectin is an adipocyte-derived secretory factor that is specifically produced in adipocytes. It exerts effects on energy homeostasis via peripheral and central mechanisms. However, it is not clear whether adiponectin crosses the blood–brain barrier in humans. In serum, adiponectin circulates in several different complexes, each of which has distinct functions. Here, we wanted to test whether adiponectin can be found in human cerebrospinal fluid (CSF) and whether specific adiponectin complexes are enriched in CSF compared with peripheral serum samples. We also wanted to establish whether there is a sex-related difference with regard to the distribution of adiponectin oligomers in CSF.

Materials and methods

We studied 22 subjects (11 men, 11 women) in this study. Their average BMI was 28.0 ± 4.7 kg/m2; average age was 70 ± 7 years.

Results

Analysis of total adiponectin revealed that adiponectin protein is present in human CSF at approximately 0.1% of serum concentration. The distribution of adiponectin oligomers differs considerably in CSF from that of serum within matched samples from the same patients. Only the adiponectin trimeric and low-molecular-mass hexameric complexes are found in CSF, with a bias towards the trimeric form in most patients. Male subjects have a higher CSF:serum ratio of total adiponectin (p < 0.05; n = 20) and have slightly higher trimer levels in serum and CSF than female subjects.

Conclusions/interpretation

We conclude that the adiponectin trimer is the predominant oligomer in human CSF.
Literature
1.
Ahima RS, Flier JS (2000) Adipose tissue as an endocrine organ. Trends Endocrinol Metab 11:327–332PubMedCrossRef
2.
Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395:763–770PubMedCrossRef
3.
Elmquist JK, Elias CF, Saper CB (1999) From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 22:221–232PubMedCrossRef
4.
Zlokovic BV, Jovanovic S, Miao W et al (2000) Differential regulation of leptin transport by the choroid plexus and blood–brain barrier and high affinity transport systems for entry into hypothalamus and across the blood–cerebrospinal fluid barrier. Endocrinology 141:1434–1441PubMedCrossRef
5.
Scherer PE, Williams S, Fogliano M et al (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746–26749PubMedCrossRef
6.
Pajvani UB, Du X, Combs TP et al (2003) Structure–function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 278:9073–9085PubMedCrossRef
7.
Tsao TS, Lodish HF, Fruebis J (2002) ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol 440:213–221PubMedCrossRef
8.
Yamauchi T, Kamon J, Waki H et al (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941–946PubMedCrossRef
9.
Berg AH, Combs TP, Du X et al (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947–953PubMedCrossRef
10.
Combs TP, Berg AH, Rajala MW et al (2003) Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes 52:268–276PubMed
11.
Yamauchi T, Kamon J, Waki H et al (2003) Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461–2468PubMedCrossRef
12.
Nawrocki AR, Rajala MW, Tomas E et al (2006) Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 281:2654–2660PubMedCrossRef
13.
Okamoto H, Obici S, Accili D et al (2005) Restoration of liver insulin signaling in Insr knockout mice fails to normalize hepatic insulin action. J Clin Invest 115:1314–1322PubMedCrossRef
14.
Cherrington AD (2005) The role of hepatic insulin receptors in the regulation of glucose production. J Clin Invest 115:1136–1139PubMedCrossRef
15.
Berg AH, Combs TP, Scherer PE (2002) ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13:84–89PubMedCrossRef
16.
Arita Y, Kihara S, Ouchi N et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83PubMedCrossRef
17.
Fruebis J, Tsao TS, Javorschi S et al (2001) Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005–2010PubMedCrossRef
18.
Combs TP, Pajvani UB, Berg AH et al (2004) A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145:367–383PubMedCrossRef
19.
Pajvani UB, Hawkins M, Combs TP et al (2004) Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279:12152–12162PubMedCrossRef
20.
Qi Y, Takahashi N, Hileman SM et al (2004) Adiponectin acts in the brain to decrease body weight. Nat Med 10:524–529PubMedCrossRef
21.
Yamauchi T, Kamon J, Ito Y et al (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762–769PubMedCrossRef
22.
Spranger J, Verma S, Gohring I et al (2006) Adiponectin does not cross the blood–brain barrier but modifies cytokine expression of brain endothelial cells. Diabetes 55:141–147PubMedCrossRef
23.
Pan W, Tu H, Kastin AJ (2006) Differential BBB interactions of three ingestive peptides: obestatin, ghrelin, and adiponectin. Peptides 27:911–916PubMedCrossRef
24.
Mathews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRef
25.
Waki H, Yamauchi T, Kamon J et al (2003) Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 278:40352–40363PubMedCrossRef
26.
Tonelli J, Li W, Kishore P et al (2004) Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 53:1621–1629PubMed
27.
Fisher FF, Trujillo ME, Hanif W et al (2005) Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia 48:1084–1087PubMedCrossRef
28.
Wang Y, Lam KS, Xu JY et al (2005) Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 280:18341–18347PubMedCrossRef
29.
Lara-Castro C, Luo N, Wallace P et al (2006) Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 55:249–259PubMedCrossRef
30.
Hara K, Horikoshi M, Yamauchi T et al (2006) Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 29:1357–1362PubMedCrossRef
31.
Schwartz MW, Peskind E, Raskind M et al (1996) Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat Med 2:589–593PubMedCrossRef
32.
Caro JF, Kolaczynski JW, Nyce MR et al (1996) Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 348:159–161PubMedCrossRef
33.
Wiedenhoft A, Muller C, Stenger R et al (1999) Lack of sex difference in cerebrospinal fluid (CSF) leptin levels and contribution of CSF/plasma ratios to variations in body mass index in children. J Clin Endocrinol Metab 84:3021–3024, Erratum in: J Clin Endocrinol Metab (1999) 84:4171PubMedCrossRef
34.
Sinha MK, Ohannesian JP, Heiman ML et al (1996) Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. J Clin Invest 97:1344–1347PubMed
35.
Schoeller DA, Cella LK, Sinha MK et al (1997) Entrainment of the diurnal rhythm of plasma leptin to meal timing. J Clin Invest 100:1882–1887PubMedCrossRef
36.
Wong ML, Licinio J, Yildiz BO et al (2004) Simultaneous and continuous 24-hour plasma and cerebrospinal fluid leptin measurements: dissociation of concentrations in central and peripheral compartments. J Clin Endocrinol Metab 89:258–265PubMedCrossRef
37.
Kim CH, Pennisi P, Zhao H et al (2006) MKR mice are resistant to the metabolic actions of both insulin and adiponectin: discordance between insulin resistance and adiponectin responsiveness. Am J Physiol Endocrinol Metab 291:E298–E305PubMedCrossRef
38.
Pan W, Akerstrom V, Zhang J et al (2004) Modulation of feeding-related peptide/protein signals by the blood–brain barrier. J Neurochem 90:455–461PubMedCrossRef
39.
Dinulescu DM, Cone RD (2000) Agouti and agouti-related protein: analogies and contrasts. J Biol Chem 275:6695–6698PubMedCrossRef
40.
Masaki T, Chiba S, Yasuda T et al (2003) Peripheral, but not central, administration of adiponectin reduces visceral adiposity and upregulates the expression of uncoupling protein in agouti yellow (Ay/a) obese mice. Diabetes 52:2266–2273PubMed
41.
Balthasar N, Coppari R, McMinn J et al (2004) Leptin receptor signaling in POMC neurons is required for normal body weight homeostasis. Neuron 42:983–991PubMedCrossRef
42.
Nishizawa H, Shimomura I, Kishida K et al (2002) Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51:2734–2741PubMed
43.
Cnop M, Havel PJ, Utzschneider KM et al (2003) Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46:459–469PubMed
44.
Xu A, Chan KW, RL Hoo et al (2005) Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 280:18073–18080PubMedCrossRef
Metadata
Title
Adiponectin complexes in human cerebrospinal fluid: distinct complex distribution from serum
Authors
C. M. Kusminski
P. G. McTernan
T. Schraw
K. Kos
J. P. O’Hare
R. Ahima
S. Kumar
P. E. Scherer
Publication date
01-03-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 3/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0577-9

Other articles of this Issue 3/2007

Diabetologia 3/2007 Go to the issue

Letter

Comment on: Distiller LA, Joffe BI (2006) From the coalface: does glargine insulin improve hypoglycaemic episodes, glycaemic control or affect body mass in type 1 diabetic subjects who are attending a ‘routine’ diabetes clinic? Diabetologia 49:2793–2794

For Debate

C-peptide: a redundant relative of insulin?

Short Communication

Does self-monitoring of blood glucose improve outcome in type 2 diabetes? The Fremantle Diabetes Study

Article

Single nucleotide polymorphisms in the neuropeptide Y2 receptor (NPY2R) gene and association with severe obesity in French white subjects

Article

Pre-eclampsia but not pregnancy-induced hypertension is a risk factor for diabetic nephropathy in type 1 diabetic women

Article

Adenoviral overproduction of interleukin-1 receptor antagonist increases beta cell replication and mass in syngeneically transplanted islets, and improves metabolic outcome
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits